Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate; maize starch; stearic acid; amaranth aluminium lake; indigo carmine aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; lactose; magnesium stearate; quinoline yellow aluminium lake; brilliant blue fcf aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: stearic acid; magnesium stearate; maize starch; lactose; quinoline yellow aluminium lake; amaranth aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.

United States - English - NLM (National Library of Medicine)

bristol-myers squibb pharma company - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. coumadin is contraindicated in: • pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and use in specific populations (8.1)] . coumadin can cause fetal harm when administered to a pregnant woman. coumadin exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. if coumadin is used during pregnancy or if the patient becomes pregn

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. - pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.5) and use in specific populations (8.1) ]. c

United States - English - NLM (National Library of Medicine)

cardinal health - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. coumadin is contraindicated in: • pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and use in specific populations (8.1)] . coumadin can cause fetal harm when administered to a pregnant woman. coumadin exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. if coumadin is used during pregnancy or if the patient becomes pregn

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. - pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.5) and use in specific populations (8.1) ]. c

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - tablets - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.